References
- Basma HA, Kobeissi LH, Jabbour ME, Moussa MA and Dhaini HR (2013). CYP2E1 and NQO1 genotypes and bladder cancer risk in a Lebanese population. Int J Mol Epidemiol Genet, 4, 207-17.
- Brockmoller J, Cascorbi I, Kerb R and Roots I (1996). Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res, 56, 3915-25.
- Cantor KP, Villanueva CM, Silverman DT, et al (2010). Polymorphisms in GSTT1, GSTZ1, and CYP2E1, disinfection by-products, and risk of bladder cancer in Spain. Environ Health Perspect, 118, 1545-50. https://doi.org/10.1289/ehp.1002206
- Carriere V, Berthou F, Baird S, et al (1996). Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics, 6, 203-11. https://doi.org/10.1097/00008571-199606000-00002
- Choi JY, Lee KM, Cho SH, et al (2003). CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics, 13, 349-55. https://doi.org/10.1097/00008571-200306000-00006
- Clapp RW, Jacobs MM and Loechler EL (2008). Environmental and occupational causes of cancer: new evidence 2005-2007. Rev Environ Health, 23, 1-37. https://doi.org/10.1515/REVEH.2008.23.1.1
- Danko IM and Chaschin NA (2005). Association of CYP2E1 gene polymorphism with predisposition to cancer development. Exp Oncol, 27, 248-56.
- DerSimonian R and Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
- Gonzalez FJ (2005). Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat Res, 569, 101-10. https://doi.org/10.1016/j.mrfmmm.2004.04.021
- Guengerich FP, Kim DH and Iwasaki M (1991). Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol, 4, 168-79. https://doi.org/10.1021/tx00020a008
- Hayashi S, Watanabe J and Kawajiri K (1991). Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem, 110, 559-65. https://doi.org/10.1093/oxfordjournals.jbchem.a123619
- Higgins JP and Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
- Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A and Vainio H (1993). The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis, 14, 85-8. https://doi.org/10.1093/carcin/14.1.85
- Hoeijmakers JH (2001). Genome maintenance mechanisms for preventing cancer. Nature, 411, 366-74. https://doi.org/10.1038/35077232
- Johansson I, Lindros KO, Eriksson H and Ingelman-Sundberg M (1990). Transcriptional control of CYP2E1 in the perivenous liver region and during starvation. Biochem Biophys Res Commun, 173, 331-8. https://doi.org/10.1016/S0006-291X(05)81061-7
- Kim RB and O'Shea D (1995). Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther, 57, 645-55. https://doi.org/10.1016/0009-9236(95)90227-9
- Kim RB, Yamazaki H, Chiba K, et al (1996). In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther, 279, 4-11.
- Ladero JM, Agundez JA, Rodriguez-Lescure A, Diaz-Rubio M and Benitez J (1996). RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma. Gut, 39, 330-3. https://doi.org/10.1136/gut.39.2.330
- Lakkakula S, Maram R, Munirajan AK, et al (2013). Functional PstI/RsaI polymorphisms in the CYP2E1 gene among south Indian populations. Asian Pac J Cancer Prev, 14, 179-82. https://doi.org/10.7314/APJCP.2013.14.1.179
- Le Marchand L, Sivaraman L, Pierce L, et al (1998). Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res, 58, 4858-63.
- Leng WD, Zeng XT, Chen YJ, et al (2012). Cytochrome P450 2E1 RsaI/PstI polymorphism and risk of esophageal cancer: A meta-analysis of 17 case-control studies. Exp Ther Med, 4, 938-948. https://doi.org/10.3892/etm.2012.687
- Lin DX, Tang YM, Peng Q, et al (1998). Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1. Cancer Epidemiol Biomarkers Prev, 7, 1013-8.
- London SJ, Daly AK, Cooper J, et al (1996). Lung cancer risk in relation to the CYP2E1 Rsa I genetic polymorphism among African-Americans and Caucasians in Los Angeles County. Pharmacogenetics, 6, 151-8. https://doi.org/10.1097/00008571-199604000-00002
- Lucas D, Menez C, Girre C, et al (1995). Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics, 5, 298-304. https://doi.org/10.1097/00008571-199510000-00005
- Mantel N and Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
- Mittal RD, Srivastava DS, A M and B M (2005). Genetic polymorphism of drug metabolizing enzymes (CYP2E1, GSTP1) and susceptibility to bladder cancer in North India. Asian Pac J Cancer Prev, 6, 6-9.
- Munafo MR and Flint J (2004). Meta-analysis of genetic association studies. Trends Genet, 20, 439-44. https://doi.org/10.1016/j.tig.2004.06.014
- Pandith AA, Lateef A, Shahnawaz S, et al (2013). GSTP1 gene Ile105Val polymorphism causes an elevated risk for bladder carcinogenesis in smokers. Asian Pac J Cancer Prev, 14, 6375-8. https://doi.org/10.7314/APJCP.2013.14.11.6375
- Parkin DM (2008). The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl, 12-20.
- Persson I, Johansson I, Bergling H, et al (1993). Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett, 319, 207-11. https://doi.org/10.1016/0014-5793(93)80547-8
- Shahriary GM, Galehdari H, Jalali A, et al (2012). CYP2E1*5B, CYP2E1*6, CYP2E1*7B, CYP2E1*2, and CYP2E1*3 allele frequencies in iranian populations. Asian Pac J Cancer Prev, 13, 6505-10. https://doi.org/10.7314/APJCP.2012.13.12.6505
- Shao J, Gu M, Zhang Z, et al (2008). Genetic variants of the cytochrome P450 and glutathione S-transferase associated with risk of bladder cancer in a south-eastern Chinese population. Int J Urol, 15, 216-21. https://doi.org/10.1111/j.1442-2042.2007.01915.x
- Sheweita SA, Abu El-Maati MR, El-Shahat FG and Bazeed MA (2001). Changes in the expression of cytochrome P450 2E1 and the activity of carcinogen-metabolizing enzymes in Schistosoma haematobium-infected human bladder tissues. Toxicology, 162, 43-52. https://doi.org/10.1016/S0300-483X(01)00357-2
- Steck SE and Hebert JR (2009). GST polymorphism and excretion of heterocyclic aromatic amine and isothiocyanate metabolites after Brassica consumption. Environ Mol Mutagen, 50, 238-46. https://doi.org/10.1002/em.20456
- Stephens EA, Taylor JA, Kaplan N, et al (1994). Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics, 4, 185-92. https://doi.org/10.1097/00008571-199408000-00002
- Strope SA and Montie JE (2008). The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation. J Urol, 180, 31-7; discussion 37. https://doi.org/10.1016/j.juro.2008.03.045
- Taioli E and Raimondi S (2005). Genetic susceptibility to bladder cancer. Lancet, 366, 610-2. https://doi.org/10.1016/S0140-6736(05)67115-2
- Tian Z, Li YL, Zhao L and Zhang CL (2012). CYP2E1 RsaI/PstI polymorphism and liver cancer risk among east Asians: a HuGE review and meta-analysis. Asian Pac J Cancer Prev, 13, 4915-21. https://doi.org/10.7314/APJCP.2012.13.10.4915
- Uematsu F, Kikuchi H, Ohmachi T, et al (1991). Two common RFLPs of the human CYP2E gene. Nucleic Acids Res, 19, p. 2803.
- Wang Y, Yang H, Li L, et al (2009). Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis. Eur J Cancer, 46, 758-64.
- Yamazaki H, Inui Y, Yun CH, Guengerich FP and Shimada T (1992). Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis, 13, 1789-94. https://doi.org/10.1093/carcin/13.10.1789
- Yu MW, Gladek-Yarborough A, Chiamprasert S, et al (1995). Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology, 109, 1266-73. https://doi.org/10.1016/0016-5085(95)90587-1
- Yue J, Peng R, Chen J, Liu Y and Dong G (2009). Effects of rifampin on CYP2E1-dependent hepatotoxicity of isoniazid in rats. Pharmacol Res, 59, 112-9. https://doi.org/10.1016/j.phrs.2008.10.006
- Zabost A, Zwolska Z and Augustynowicz-Kopec E (2013). [The biological role of prokaryotic and eukaryotic N-acetyltransferase]. Pneumonol Alergol Pol, 81, 137-44.
- Zgheib NK, Mitri Z, Geryess E and Noutsi P (2010). Cytochrome P4502E1 (CYP2E1) genetic polymorphisms in a Lebanese population: frequency distribution and association with morbid diseases. Genet Test Mol Biomarkers, 14, 393-7. https://doi.org/10.1089/gtmb.2009.0193
- Zhang X, Lin J, Wu X, et al (2012). Association between GSTM1 copy number, promoter variants and susceptibility to urinary bladder cancer. Int J Mol Epidemiol Genet, 3, 228-36.
Cited by
- Significant Genotype Difference in the CYP2E1 PstI Polymorphism of Indigenous Groups in Sabah, Malaysia with Asian and Non-Asian Populations vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7377
- 2,4-Dimethylaniline generates phosphorylated histone H2AX in human urothelial and hepatic cells through reactive oxygen species produced by cytochrome P450 2E1 vol.92, pp.10, 2018, https://doi.org/10.1007/s00204-018-2289-6